Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

α-Methylisotryptamine

From Wikipedia, the free encyclopedia
Monoaminergic drug

Pharmaceutical compound
α-Methylisotryptamine
Clinical data
Other namesisoAMT; iso-αMT; α-Me-isoT; PAL-569; 1-α-Methyltryptamine; 1-(2-Aminopropyl)indole; 1-API; 1-IT; α-Methyl-isotryptamine
Drug classSerotonin–norepinephrine releasing agent;Serotonin receptor agonist
Identifiers
  • 1-indol-1-ylpropan-2-amine
CAS Number
PubChemCID
ChemSpider
Chemical and physical data
FormulaC11H14N2
Molar mass174.247 g·mol−1
3D model (JSmol)
  • CC(CN1C=CC2=CC=CC=C21)N
  • InChI=1S/C11H14N2/c1-9(12)8-13-7-6-10-4-2-3-5-11(10)13/h2-7,9H,8,12H2,1H3
  • Key:OZPPCCIRSILHOZ-UHFFFAOYSA-N

α-Methylisotryptamine (isoAMT orα-Me-isoT) is a synthetic compound belonging to theisotryptamine family, known for its psychoactive properties. As a structural analog of α-methyltryptamine (αMT), isoAMT exhibitsentactogenic andpsychedelic effects.

Pharmacology

[edit]

α-Methylisotryptamine is amonoamine releasing agent andserotonin receptor agonist of theisotryptamine group.[1][2][3][4] It is the isotryptaminehomologue ofα-methyltryptamine (αMT), which is a more well-knownserotonergic psychedelic,entactogen, andstimulant of thetryptamine family with similarpharmacologicalactions.[4][5][6]

Like αMT, α-methylisotryptamine is amonoamine releasing agent.[1][2] As the (–)-enantiomer, it specifically acts as a preferentialserotonin and norepinephrine releasing agent (SNRA), withEC50Tooltip half-maximal effective concentration values of 177 nM forserotonin release, 81 nM fornorepinephrine release, and 1,062 nM fordopamine release.[1][2] In contrast toamphetamine and similar agents acting aspotent andselectivedopamine and norepinephrine releasing agents, (–)-α-methylisotryptamine showed nomisuse potential inanimal studies, including nococaine-like effects indrug discrimination tests and no facilitation ofintracranial self-stimulation (ICSS).[1][2] In addition to its monoamine release, α-methylisotryptamine showsaffinity for serotonin5-HT2 receptors.[3]

Analogs

[edit]

Aderivative of α-methylisotryptamine,zalsupindole (DLX-001; AAZ-A-154; (R)-5-MeO-N,N-dimethyl-isoAMT), is a non-hallucinogenic serotonin5-HT2A receptoragonist and is being developed for potential medical use in the treatmentdepression and otherneuropsychiatric disorders.[7][8][9][10][11] Other derivatives of α-methylisotryptamine have also been developed, such as the selective serotonin5-HT2C receptor agonists (S)-5,6-difluoro-isoAMT andRo60-0175 ((S)-5-fluoro-6-chloro-isoAMT), among others.[12][13][14][15][16]

See also

[edit]

References

[edit]
  1. ^abcdBauer CT (5 July 2014).Determinants of Abuse-Related Effects of Monoamine Releasers in Rats.VCU Scholars Compass (Thesis).doi:10.25772/AN08-SZ65. Retrieved24 November 2024.
  2. ^abcdBanks ML, Bauer CT, Blough BE, Rothman RB, Partilla JS, Baumann MH, et al. (June 2014)."Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys".Experimental and Clinical Psychopharmacology.22 (3):274–284.doi:10.1037/a0036595.PMC 4067459.PMID 24796848.
  3. ^abLyon RA, Titeler M, Seggel MR, Glennon RA (January 1988). "Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens".European Journal of Pharmacology.145 (3):291–297.doi:10.1016/0014-2999(88)90432-3.PMID 3350047.
  4. ^ab"1-(1H-Indol-1-yl)propan-2-amine".PubChem. Retrieved24 November 2024.
  5. ^Oeri HE (May 2021)."Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy".Journal of Psychopharmacology.35 (5):512–536.doi:10.1177/0269881120920420.PMC 8155739.PMID 32909493.
  6. ^Glennon RA, Dukat MG (December 2023)."α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant".ACS Pharmacology & Translational Science.6 (12):1780–1789.doi:10.1021/acsptsci.3c00139.PMC 10714429.PMID 38093842.
  7. ^Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants".Chemical Reviews.124 (1):124–163.doi:10.1021/acs.chemrev.3c00375.PMID 38033123.
  8. ^Atiq MA, Baker MR, Voort JL, Vargas MV, Choi DS (May 2024)."Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties".Psychopharmacology.242 (7):1481–1506.doi:10.1007/s00213-024-06599-5.PMC 12226698.PMID 38743110.
  9. ^"DLX 1".AdisInsight. 11 December 2023. Retrieved2 November 2024.
  10. ^"Delving into the Latest Updates on DLX-001 with Synapse".Synapse. 1 November 2024. Retrieved2 November 2024.
  11. ^Rasmussen K, Engel S, Chytil M, Koenig A, Meyer R, Rus M, et al. (December 2023)."ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500: P361. Preclinical Pharmacology of DLX-001, a Novel Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases".Neuropsychopharmacology.48 (Suppl 1): 211–354 (274–275).doi:10.1038/s41386-023-01756-4.PMC 10729596.PMID 38040810.
  12. ^Chang-Fong J, Addo J, Dukat M, Smith C, Mitchell NA, Herrick-Davis K, et al. (January 2002). "Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors".Bioorganic & Medicinal Chemistry Letters.12 (2):155–158.doi:10.1016/s0960-894x(01)00713-2.PMID 11755343.
  13. ^Nilsson BM (July 2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents".Journal of Medicinal Chemistry.49 (14):4023–4034.doi:10.1021/jm058240i.PMID 16821762.
  14. ^Bishop MJ, Nilsson BM (2003). "New 5-HT2C receptor agonists".Expert Opinion on Therapeutic Patents.13 (11):1691–1705.doi:10.1517/13543776.13.11.1691.ISSN 1354-3776.
  15. ^Isaac M (2005). "Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs".Current Topics in Medicinal Chemistry.5 (1):59–67.doi:10.2174/1568026053386980.PMID 15638778.
  16. ^Bös M, Jenck F, Martin JR, Moreau JL, Sleight AJ, Wichmann J, et al. (August 1997). "Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder".J Med Chem.40 (17):2762–2769.doi:10.1021/jm970030l.PMID 9276022.
DRAsTooltip Dopamine releasing agents
NRAsTooltip Norepinephrine releasing agents
SRAsTooltip Serotonin releasing agents
Others
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Α-Methylisotryptamine&oldid=1322837223"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp